The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p

Nature Communications

Volumn 6, Issue , 2015, Pages

  Towers, Christina G ^a   Guarnieri, Anna L ^a,b,c   Micalizzi, Doug S ^a,e   Harrell, J Chuck ^d   Gillen, Austin E ^a   Kim, Jihye ^a   Wang, Chu An ^a,f   Oliphant, Michael U J ^a   Drasin, David J ^a,g   Guney, Michelle A ^a   Kabos, Peter ^a   Sartorius, Carol A ^a   Tan, Aik Choon ^a   Perou, Charles M ^d   Espinosa, Joaquin M ^a,b,c   Ford, Heide L ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^g NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CYCLIN D1; ETOPOSIDE; HISTONE DEACETYLASE 1; MICRORNA; MICRORNA 27A; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUTLIN 3; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; RIBOSOMAL PROTEIN L26; RIBOSOME PROTEIN; TRANSCRIPTION FACTOR SIX1; UNCLASSIFIED DRUG; HOMEODOMAIN PROTEIN; MIRN27 MICRORNA, HUMAN; RPL26 PROTEIN, HUMAN; SIX1 PROTEIN, HUMAN;

CANCER; DRUG; GENE EXPRESSION; MUTATION; PROTEIN; TUMOR;

ARTICLE; BREAST CANCER; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; TUMOR CELL LINE;

CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MICRORNAS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; RIBOSOMAL PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84951910396     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10077     Document Type: Article

References (69)

1. Toledo, F., Wahl, G. M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6, 909-923 (2006).
2. Wade, M., Li, Y. C.,Wahl, G. M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer 13, 83-96 (2013).
3. Dai, C., Gu, W. p53 post-translational modification: deregulated in tumorigenesis. Trends Mol. Med. 16, 528-536 (2010).
4. Zhang, J. et al. Translational repression of p53 by RNPC1, a p53 target overexpressed in lymphomas. Genes Dev. 25, 1528-1543 (2011).
5. Kim, D. Y. et al. hnRNP Q regulates translation of p53 in normal and stress conditions. Cell Death Differ. 20, 226-234 (2013).
6. Mazan-Mamczarz, K. et al. RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc. Natl Acad. Sci. USA 100, 8354-8359 (2003).
7. Yang, D. Q., Halaby, M. J., Zhang, Y. The identification of an internal ribosomal entry site in the 50-untranslated region of p53 mRNA provides a novel mechanism for the regulation of its translation following DNA damage. Oncogene 25, 4613-4619 (2006).
8. Yin, Y., Stephen, C. W., Luciani, M. G., Fahraeus, R. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat. Cell Biol. 4, 462-467 (2002).
9. Candeias, M. M. et al. P53 mRNA controls p53 activity by managing Mdm2 functions. Nat. Cell Biol. 10, 1098-1105 (2008).
10. Takagi, M., Absalon, M. J., McLure, K. G., Kastan, M. B. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 123, 49-63 (2005).
11. Chen, J., Kastan, M. B. 50-30-UTR interactions regulate p53 mRNA translation and provide a target for modulating p53 induction after DNA damage. Genes Dev. 24, 2146-2156 (2010).
12. Krell, J. et al. The p53 miRNA interactome and its potential role in the cancer clinic. Epigenomics 5, 417-428 (2013).
13. Xu, P. X. The EYA-SO/SIX complex in development and disease. Pediatr. Nephrol. 28, 843-854 (2013).
14. Blevins, M. A., Towers, C. G., Patrick, A. N., Zhao, R., Ford, H. L. The SIX1-EYA transcriptional complex as a therapeutic target in cancer. Expert Opin. Ther. Targets 19, 213-225 (2015).
15. Wang, C. A. et al. SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer. J. Clin. Invest. 122, 1895-1906 (2012).
16. Micalizzi, D. S. et al. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J. Clin. Invest. 119, 2678-2690 (2009).
17. Iwanaga, R. et al. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res. 14, R100 (2012).
18. Smith, A. L. et al. The miR-106b-25 cluster targets Smad7, activates TGF-beta signaling, induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene 31, 5162-5171 (2012).
19. McCoy, E. L. et al. Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J. Clin. Invest. 119, 2663-2677 (2009).
20. Pfefferle, A. D. et al. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol. 14, R125 (2013).
21. Coletta, R. D. et al. Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation. Cancer Res. 68, 2204-2213 (2008).
22. Gomes, N. P. et al. Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. Genes Dev. 20, 601-612 (2006).
23. Bieging, K. T., Mello, S. S., Attardi, L. D. Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer 14, 359-370 (2014).
24. Wu, W. et al. Six1: a critical transcription factor in tumorigenesis. Int. J. Cancer 136, 1245-1253 (2015).
25. Wade, M., Wang, Y. V., Wahl, G. M. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell. Biol. 20, 299-309 (2010).
26. Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).
27. Barretina, J. et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat. Genet. 42, 715-721 (2010).
28. The Cancer Genome Atlas (TCGA) Research Network. The Cancer Genome Atlas-Invasive Breast Carcinoma Gene Expression Data. Available at http://tcga-data.nci.nih.gov/tcga/(2011).
29. Lee, J. T., Gu, W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ. 17, 86-92 (2010).
30. Li, Z. et al. Six1 promotes proliferation of pancreatic cancer cells via upregulation of cyclin D1 expression. PloS One 8, e59203 (2013).
31. (MSKCC), C. B. C. a. M. S.-K. C. C. microRNA.org-Targets and Expression omicroRNA.org4 (2010).
32. Liu, T., Tang, H., Lang, Y., Liu, M., Li, X. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett. 273, 233-242 (2009).
33. Wang, X. et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PloS One 3, e2557 (2008).
34. Mertens-Talcott, S. U., Chintharlapalli, S., Li, X., Safe, S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 67, 11001-11011 (2007).
35. Zhang, Z., Liu, S., Shi, R., Zhao, G. miR-27 promotes human gastric cancer cell metastasis by inducing epithelial-to-mesenchymal transition. Cancer Genet. 204, 486-491 (2011).
36. Zhang, H. et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig. Dis. Sci. 55, 2545-2551 (2010).
37. Pillai, M. M. et al. HITS-CLIP reveals key regulators of nuclear receptor signaling in breast cancer. Breast Cancer Res. Treat. 146, 85-97 (2014).
38. Enerly, E. et al. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS ONE 6, e16915 (2011).
39. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352 (2012).
40. Gaedcke, J. et al. Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosomes Cancer 49, 1024-1034 (2010).
41. Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012).
42. Selamat, S. A. et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 22, 1197-1211 (2012).
43. Ma, X. J. et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5, 607-616 (2004).
44. van't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
45. Biewenga, P. et al. Gene expression in early stage cervical cancer. Gynecol. Oncol. 108, 520-526 (2008).
46. Cui, J. et al. An integrated transcriptomic and computational analysis for biomarker identification in gastric cancer. Nucleic Acids Res. 39, 1197-1207 (2011).
47. Patrick, A. N. et al. Structure-function analyses of the human SIX1-EYA2 complex reveal insights into metastasis and BOR syndrome. Nat. Struct. Mol. Biol. 20, 447-453 (2013).
48. Behbakht, K. et al. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res. 67, 3036-3042 (2007).
49. Ma, X. J., Dahiya, S., Richardson, E., Erlander, M., Sgroi, D. C. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 11, R7 (2009).
50. Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14, 518-527 (2008).
51. Lee, J. S. et al. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J. Clin. Oncol. 28, 2660-2667 (2010).
52. Kim, S. M. et al. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS ONE 5, e15074 (2010).
53. Chandran, U. R. et al. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 7, 64 (2007).
54. Ben-Ami, O., Pencovich, N., Lotem, J., Levanon, D., Groner, Y. A regulatory interplay between miR-27a and Runx1 during megakaryopoiesis. Proc. Natl Acad. Sci. USA 106, 238-243 (2009).
55. Xu, L. et al. Oncogenic microRNA-27a is a target for genistein in ovarian cancer cells. Anticancer Agents Med. Chem. 13, 1126-1132 (2013).
56. Kumar, J. P. The sine oculis homeobox (SIX) family of transcription factors as regulators of development and disease. Cell. Mol. Life Sci. 66, 565-583 (2009).
57. Zhang, Y., Lu, H. Signaling to p53: ribosomal proteins find their way. Cancer Cell 16, 369-377 (2009).
58. Ho, J. J., Marsden, P. A. Competition and collaboration between RNAbinding proteins and microRNAs. Wiley Interdiscip.y Rev. RNA 5, 69-86 (2014).
59. Ho, J. J. et al. Active stabilization of human endothelial nitric oxide synthase mRNA by hnRNP E1 protects against antisense RNA and microRNAs. Mol. Cell. Biol. 33, 2029-2046 (2013).
60. Young, L. E., Moore, A. E., Sokol, L., Meisner-Kober, N., Dixon, D. A. The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2. Mol. Cancer Res. 10, 167-180 (2012).
61. Tovar, C. et al. Small-molecule MDM2 antagonists reveal aberrant p53 signalling in cancer: implications for therapy. Proc. Natl Acad. Sci. USA 103, 1888-1893 (2006).
62. Ford, H. L., Kabingu, E. N., Bump, E. A., Mutter, G. L., Pardee, A. B. Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcinogenesis. Proc. Natl Acad. Sci. USA 95, 12608-12613 (1998).
63. R Core Team, R Foundation for Statistical Computing. R: A Language and Environment for Statistical Computing. Available at https://www.r-project.org/(1991).
64. Chi, S. W., Zang, J. B., Mele, A., Darnell, R. B. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 460, 479-486 (2009).
65. Balakrishnan, I. et al. Genome-wide analysis of miRNA-mRNA interactions in marrow stromal cells. Stem Cells 32, 662-673 (2014).
66. Ford, H. L. et al. Cell cycle-regulated phosphorylation of the human SIX1 homeodomain protein. J. Biol. Chem. 275, 22245-22254 (2000).
67. Kabos, P. et al. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res. Treat 135, 415-432 (2012).
68. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
69. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).